Connect
MJA
MJA

Funding of new cardiac technologies in Australia

David W M Muller
Med J Aust 2012; 197 (3): 132-133. || doi: 10.5694/mja12.10994
Published online: 6 August 2012

A scarcity of funding resources is limiting patient access to major advances in medicine

Health care spending represents a substantial and increasing proportion of national expenditure in most countries. Total annual health care spending in Australia now exceeds $120 billion, or 9.4% of gross domestic product.1 The highest proportion of health care funding is spent on cardiovascular disease, which accounted for 11% of total expenditure in the 2008–09 financial year.1 Rapid advances in pharmacotherapy and device technology are constantly pressuring funding sources. New cardiovascular technologies, including drug-eluting stents, implantable defibrillators, left ventricular assist devices, and devices for structural heart disease, are undoubtedly major advances, but access to the devices has often outpaced the availability of funding to pay for them.

  • David W M Muller

  • Cardiology Department, St Vincent’s Hospital, Sydney, NSW.

Correspondence: dmuller@stvincents.com.au

Competing interests:

I have received research support and honoraria from various device companies, including Abbott Vascular, Medtronic and Boston Scientific.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.